CN1615440A - 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 - Google Patents

含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 Download PDF

Info

Publication number
CN1615440A
CN1615440A CNA028271920A CN02827192A CN1615440A CN 1615440 A CN1615440 A CN 1615440A CN A028271920 A CNA028271920 A CN A028271920A CN 02827192 A CN02827192 A CN 02827192A CN 1615440 A CN1615440 A CN 1615440A
Authority
CN
China
Prior art keywords
angptl3
tissue
liver
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028271920A
Other languages
English (en)
Chinese (zh)
Inventor
纳波莱昂内·费拉拉
汉斯-彼得·格伯
乔·科沃尔斯基
玛丽亚·T·皮萨巴罗
丹尼尔·E·舍曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN1615440A publication Critical patent/CN1615440A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
CNA028271920A 2001-11-16 2002-11-13 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 Pending CN1615440A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33242901P 2001-11-16 2001-11-16
US60/332,429 2001-11-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010102426068A Division CN101905024A (zh) 2001-11-16 2002-11-13 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN1615440A true CN1615440A (zh) 2005-05-11

Family

ID=23298191

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028271920A Pending CN1615440A (zh) 2001-11-16 2002-11-13 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
CN2010102426068A Pending CN101905024A (zh) 2001-11-16 2002-11-13 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010102426068A Pending CN101905024A (zh) 2001-11-16 2002-11-13 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法

Country Status (14)

Country Link
US (3) US7267819B2 (cg-RX-API-DMAC7.html)
EP (1) EP1451578B1 (cg-RX-API-DMAC7.html)
JP (2) JP5105696B2 (cg-RX-API-DMAC7.html)
KR (2) KR20100029861A (cg-RX-API-DMAC7.html)
CN (2) CN1615440A (cg-RX-API-DMAC7.html)
AU (1) AU2002348286B2 (cg-RX-API-DMAC7.html)
CA (1) CA2464542C (cg-RX-API-DMAC7.html)
ES (1) ES2429034T3 (cg-RX-API-DMAC7.html)
IL (2) IL161542A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04004609A (cg-RX-API-DMAC7.html)
NO (1) NO336021B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ532852A (cg-RX-API-DMAC7.html)
WO (1) WO2003044172A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403070B (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101852805A (zh) * 2009-03-31 2010-10-06 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
CN102625830A (zh) * 2009-07-14 2012-08-01 斯克里普斯研究所 间充质干细胞分化
CN101855241B (zh) * 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
CN105021827A (zh) * 2015-07-17 2015-11-04 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
CN110938144A (zh) * 2019-11-27 2020-03-31 上海市闵行区中心医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CN111122872A (zh) * 2019-11-20 2020-05-08 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
JP5349752B2 (ja) * 2003-08-21 2013-11-20 デュシェネ インク 微量栄養素サプリメント
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005269758B2 (en) * 2004-07-20 2011-11-03 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
EP1771474B1 (en) * 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
WO2009128077A1 (en) * 2008-04-14 2009-10-22 Hadasit Medical Research Services And Development Ltd. Stable cell binding chimeric peptides
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CN102687027B (zh) * 2010-02-02 2016-05-25 阿利桑那卅评议会 用于测序聚合物的受控的隧道间隙设备
US20130330752A1 (en) * 2011-01-29 2013-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
WO2013110120A1 (en) * 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CN104062432B (zh) * 2013-03-22 2016-01-20 中山大学 ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用
KR102138781B1 (ko) 2013-05-01 2020-07-28 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
DK3087183T3 (da) 2013-12-24 2020-09-14 Ionis Pharmaceuticals Inc Modulation af angiopoietin-3-lignende ekspression
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
KR20250078597A (ko) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
SG11201806176PA (en) * 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
MX2020001912A (es) 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用
CN120254294B (zh) * 2025-06-05 2025-09-09 南昌大学第一附属医院 Angptl3在乙肝相关慢加急性肝衰竭预后中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
CA2252629A1 (en) * 1997-02-26 1998-09-03 Toray Industries, Inc. Remedies for hepatitis
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) * 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2361849A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101855241B (zh) * 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
CN101852805A (zh) * 2009-03-31 2010-10-06 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
WO2010111892A1 (zh) * 2009-03-31 2010-10-07 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
CN102625830A (zh) * 2009-07-14 2012-08-01 斯克里普斯研究所 间充质干细胞分化
CN102625830B (zh) * 2009-07-14 2016-03-02 斯克里普斯研究所 间充质干细胞分化
CN105601728A (zh) * 2009-07-14 2016-05-25 斯克里普斯研究所 间充质干细胞分化
CN105601728B (zh) * 2009-07-14 2020-01-10 斯克里普斯研究所 间充质干细胞分化
CN105021827A (zh) * 2015-07-17 2015-11-04 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
CN111122872A (zh) * 2019-11-20 2020-05-08 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用
CN110938144A (zh) * 2019-11-27 2020-03-31 上海市闵行区中心医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途

Also Published As

Publication number Publication date
IL161542A0 (en) 2004-09-27
JP2010100624A (ja) 2010-05-06
EP1451578A4 (en) 2006-02-01
WO2003044172A3 (en) 2003-11-20
JP5105696B2 (ja) 2012-12-26
US20070134250A1 (en) 2007-06-14
MXPA04004609A (es) 2004-08-12
CA2464542C (en) 2015-01-20
ZA200403070B (en) 2005-06-29
US20030215451A1 (en) 2003-11-20
NZ532852A (en) 2006-08-31
US7267819B2 (en) 2007-09-11
CN101905024A (zh) 2010-12-08
KR20100029861A (ko) 2010-03-17
KR20050044485A (ko) 2005-05-12
EP1451578B1 (en) 2013-08-21
US20090098117A1 (en) 2009-04-16
CA2464542A1 (en) 2003-05-30
NO20042410L (no) 2004-06-09
IL203894A (en) 2013-09-30
WO2003044172B1 (en) 2004-03-18
KR101012904B1 (ko) 2011-02-08
WO2003044172A2 (en) 2003-05-30
EP1451578A2 (en) 2004-09-01
JP2005521643A (ja) 2005-07-21
ES2429034T3 (es) 2013-11-12
NO336021B1 (no) 2015-04-20
AU2002348286B2 (en) 2008-04-03
AU2002348286A1 (en) 2003-06-10
US8541376B2 (en) 2013-09-24

Similar Documents

Publication Publication Date Title
CN1615440A (zh) 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
CN1146440C (zh) 血管内皮生长因子-b
CN1552855A (zh) 人血管内皮生长因子2
CN1680442A (zh) 截短的vegf相关蛋白质
CN101053561A (zh) 用于抑制αvβ5介导的血管生成的方法和组合物
CN1308451C (zh) 肿瘤坏死因子相关配基
CN1236390A (zh) 血管形成因子及其在治疗心血管疾病中的用途
CN1449445A (zh) Ev－vegf核酸和多肽及使用方法
CN1541107A (zh) 生长因子复合物
CN1300367A (zh) 用于类风湿性关节炎诊断的方法和组合物
CN1420926A (zh) 抗生血管蛋白和片段及其应用方法
CN1292796A (zh) Meth1和meth2多核苷酸及多肽
CN1044125A (zh) 猴转化生长因子β1的克隆和表达
CN1745094A (zh) 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
CN1626552A (zh) 血管发生相关分子
CN1961073A (zh) 切割型dance、dance复合体及其使用方法
HK1077877A (en) Composition comprising and method of using angiopoietin-like protein 3 angptl3
CN1317047A (zh) Gbs毒素受体
CN1234728C (zh) 新的人淋巴因子、其编码序列及用途
CN1688197A (zh) 以野生型或突变型eNOS对重症肢体缺血的基因治疗
CN1414020A (zh) 成纤维细胞生长因子11的抗体、拮抗剂及激动剂
CN1238379C (zh) 新的破骨细胞形成抑制因子、其编码序列及用途
CN1166776C (zh) 人血管ibp样生长因子在制备用于诊断血管疾病或与肿瘤形成相关的新血管化的诊断剂中的应用
HK1008485B (en) Vascular endothelial growth factor-b
CN1772897A (zh) 具有多种功能的细胞因子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077877

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050511

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077877

Country of ref document: HK